<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250318041529&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250318041529&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 18 Mar 2025 08:15:30 +0000</lastbuilddate>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Covered Stent Treatment for Sinus Venosus Atrial Septal Defects: Early Promise and Potential Limitations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096298/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):757-759. doi: 10.1161/CIRCULATIONAHA.124.072394. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096298</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072394>10.1161/CIRCULATIONAHA.124.072394</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096298</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Glen Van Arsdell</dc:creator>
<dc:creator>Doff B McElhinney</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Covered Stent Treatment for Sinus Venosus Atrial Septal Defects: Early Promise and Potential Limitations</dc:title>
<dc:identifier>pmid:40096298</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072394</dc:identifier>
</item>
<item>
<title>Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):e763. doi: 10.1161/CIR.0000000000001321. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096297</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001321>10.1161/CIR.0000000000001321</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096297</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Britta Oerke</dc:creator>
<dc:creator>Max Wissmüller</dc:creator>
<dc:creator>Hanno Leuchte</dc:creator>
<dc:creator>Christian Opitz</dc:creator>
<dc:creator>Michael Halank</dc:creator>
<dc:creator>Hans-Juergen Seyfarth</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Hossein-Ardeschir Ghofrani</dc:creator>
<dc:creator>Stavros Konstantinides</dc:creator>
<dc:creator>Karen M Olsson</dc:creator>
<dc:creator>Rolf Wachter</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Behnaz Aminossadati</dc:creator>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study</dc:title>
<dc:identifier>pmid:40096297</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001321</dc:identifier>
</item>
<item>
<title>Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):e762. doi: 10.1161/CIR.0000000000001318. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096296</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001318>10.1161/CIR.0000000000001318</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096296</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Joshua K Meisner</dc:creator>
<dc:creator>Aaron Renberg</dc:creator>
<dc:creator>Eric D Smith</dc:creator>
<dc:creator>Yao-Chang Tsan</dc:creator>
<dc:creator>Brynn Elder</dc:creator>
<dc:creator>Abbey Bullard</dc:creator>
<dc:creator>Owen L Merritt</dc:creator>
<dc:creator>Sean L Zheng</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Thomas D Ryan</dc:creator>
<dc:creator>Erin M Miller</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:creator>Kimberly Y Lin</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>John C Stendahl</dc:creator>
<dc:creator>Dominic Abrams</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Michael Previs</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:40096296</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001318</dc:identifier>
</item>
<item>
<title>Response by Chan et al to Letters Regarding Article, "Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):e714-e715. doi: 10.1161/CIRCULATIONAHA.124.073360. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096295</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073360>10.1161/CIRCULATIONAHA.124.073360</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096295</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Paul S Chan</dc:creator>
<dc:creator>Saket Girotra</dc:creator>
<dc:creator>Monique A Starks</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Chan et al to Letters Regarding Article, "Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest"</dc:title>
<dc:identifier>pmid:40096295</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073360</dc:identifier>
</item>
<item>
<title>Letter by Tamirisa et al Regarding Article, "Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):e710-e711. doi: 10.1161/CIRCULATIONAHA.124.071883. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096294</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071883>10.1161/CIRCULATIONAHA.124.071883</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096294</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ketan Tamirisa</dc:creator>
<dc:creator>Ethan Lowder</dc:creator>
<dc:creator>Jim P Stimpson</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Tamirisa et al Regarding Article, "Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest"</dc:title>
<dc:identifier>pmid:40096294</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071883</dc:identifier>
</item>
<item>
<title>Letter by Shang et al Regarding Article, "Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):e712-e713. doi: 10.1161/CIRCULATIONAHA.124.071991. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096293</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071991>10.1161/CIRCULATIONAHA.124.071991</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096293</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Luxiang Shang</dc:creator>
<dc:creator>Baopeng Tang</dc:creator>
<dc:creator>Yinglong Hou</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Shang et al Regarding Article, "Race and Sex Differences in the Association of Bystander CPR for Cardiac Arrest"</dc:title>
<dc:identifier>pmid:40096293</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071991</dc:identifier>
</item>
<item>
<title>The Role of Race in Cardiovascular Disease Risk Prediction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):741-743. doi: 10.1161/CIRCULATIONAHA.124.071233. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096292</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071233>10.1161/CIRCULATIONAHA.124.071233</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096292</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Keith C Ferdinand</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Role of Race in Cardiovascular Disease Risk Prediction</dc:title>
<dc:identifier>pmid:40096292</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071233</dc:identifier>
</item>
<item>
<title>A Young Man With Syncope: What Is the Diagnosis?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):804-806. doi: 10.1161/CIRCULATIONAHA.124.072433. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096291</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072433>10.1161/CIRCULATIONAHA.124.072433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096291</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pongprueth Rujirachun</dc:creator>
<dc:creator>Svita Taveeamornrat</dc:creator>
<dc:creator>Arjbordin Winijkul</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Young Man With Syncope: What Is the Diagnosis?</dc:title>
<dc:identifier>pmid:40096291</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072433</dc:identifier>
</item>
<item>
<title>Risk of Cancer in Newborns With Congenital Heart Disease and Their Mothers: A Nationwide Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):807-809. doi: 10.1161/CIRCULATIONAHA.124.071811. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096290</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071811>10.1161/CIRCULATIONAHA.124.071811</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096290</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Gwang-Jun Choi</dc:creator>
<dc:creator>Jihye Heo</dc:creator>
<dc:creator>Seung Woo Park</dc:creator>
<dc:creator>Juyoung Sung</dc:creator>
<dc:creator>Insung Kim</dc:creator>
<dc:creator>Taegyun Park</dc:creator>
<dc:creator>Juhee Cho</dc:creator>
<dc:creator>June Huh</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk of Cancer in Newborns With Congenital Heart Disease and Their Mothers: A Nationwide Cohort Study</dc:title>
<dc:identifier>pmid:40096290</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071811</dc:identifier>
</item>
<item>
<title>The Mysterious Masks of Hypercholesterolemia: A Unique Clinical Case</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40096289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18;151(11):799-803. doi: 10.1161/CIRCULATIONAHA.124.071638. Epub 2025 Mar 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40096289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40096289</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071638>10.1161/CIRCULATIONAHA.124.071638</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40096289</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Uliana Chubykina</dc:creator>
<dc:creator>Petr Vasiluev</dc:creator>
<dc:creator>Olga Ivanova</dc:creator>
<dc:creator>Marat Ezhov</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Mysterious Masks of Hypercholesterolemia: A Unique Clinical Case</dc:title>
<dc:identifier>pmid:40096289</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071638</dc:identifier>
</item>
<item>
<title>Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40091747/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HF with improved EF, HF therapy withdrawal was rare. Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year. No association was found for BBL withdrawal, albeit with a significant heterogeneity for EF at improvement, suggesting better outcomes with continuing BBL only until EF improves up to 50%. These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with HF...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 17. doi: 10.1161/CIRCULATIONAHA.124.072855. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study assessed rates of, patient profiles, and associations with morbidity/mortality of renin-angiotensin inhibitors (RASi), angiotensin receptor-neprilysin inhibitors (ARNi), beta-blockers (BBL), and mineralocorticoid receptor antagonists (MRA) withdrawal in patients with HF with improved EF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with a first recorded EF &lt;40% and a later EF ≥40% from the Swedish HF registry between June 11, 2000, and December 31, 2023, were included in this retrospective observational study. Withdrawal was defined as a patient on treatment at the first (reduced) but not at the second (improved) registration. The association between withdrawal and time to first cardiovascular mortality/hospitalization for HF with censoring at 1 year was assessed by Cox regression model using overlap weighting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 8728 patients with HF with improved EF (median age, 70 years [25th to 75th percentile, 61-78], 2611 [29.9%] women), 96%, 94%, and 46% received RASi/ARNi, BBL, and MRA, respectively, when EF was &lt;40%. The withdrawal rates at the time of the improved EF registration were 4.4% for RASi/ARNi, 3.3% for BBL, and 17.2% for MRA. Predictors of withdrawal included lower use of other HF medications, higher EF at the later EF registration, and a longer time between the 2 EF assessments. After weighting, withdrawal was independently associated with a higher risk of cardiovascular mortality/hospitalization for HF by 38% for RASi/ARNi and 36% for MRA, but not for BBL. Withdrawal of BBL was associated with a higher risk of the primary outcome in the subgroup of patients with an improved EF of 40% to 49% versus ≥50% (<i>P</i>-interaction 0.03).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HF with improved EF, HF therapy withdrawal was rare. Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year. No association was found for BBL withdrawal, albeit with a significant heterogeneity for EF at improvement, suggesting better outcomes with continuing BBL only until EF improves up to 50%. These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with HF with improved EF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40091747/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40091747</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072855>10.1161/CIRCULATIONAHA.124.072855</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40091747</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Christian Basile</dc:creator>
<dc:creator>Felix Lindberg</dc:creator>
<dc:creator>Lina Benson</dc:creator>
<dc:creator>Federica Guidetti</dc:creator>
<dc:creator>Ulf Dahlström</dc:creator>
<dc:creator>Massimo Francesco Piepoli</dc:creator>
<dc:creator>Peter Mol</dc:creator>
<dc:creator>Raffaele Scorza</dc:creator>
<dc:creator>Aldo Pietro Maggioni</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction</dc:title>
<dc:identifier>pmid:40091747</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072855</dc:identifier>
</item>
<item>
<title>Overexpression of Wild-Type TMEM43 Improves Cardiac Function in Arrhythmogenic Right Ventricular Cardiomyopathy Type 5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40091736/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Overexpression of WT-TMEM43 improves the pathological phenotype in a mouse model of ARVC5. Adeno-associated virus-mediated delivery of WT-TMEM43 offers a promising and specific therapy for patients suffering from this highly lethal disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 17. doi: 10.1161/CIRCRESAHA.124.325848. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is the most aggressive type of ARVC, caused by a fully penetrant missense mutation (p.S358L) in TMEM43 (transmembrane protein 43). Pathologically, the disease is characterized by dilation of the cardiac chambers and fibrofatty replacement of the myocardium, which results in heart failure and sudden cardiac death. Current therapeutic options are limited, and no specific therapies targeting the primary cause of the disease have been proposed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We investigated whether overexpression of wild-type (WT) TMEM43 could overcome the detrimental effects of the mutant form. We used transgenic mouse models overexpressing either WT or mutant (S358L) TMEM43 to generate a double transgenic mouse line overexpressing both forms of the protein. In addition, we explored if systemic delivery of a codon-optimized self-complementary adeno-associated virus bearing WT-TMEM43 could improve disease progression assessed by ECG and echocardiography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Double transgenic mice overexpressing both WT and mutant TMEM43 forms showed delayed ARVC5 onset, improved cardiac contraction, and reduced ECG abnormalities compared with mice expressing S358L-TMEM43. In addition, cardiomyocyte death and myocardial fibrosis were reduced, with an overall increase in survival. Finally, we demonstrated that a single systemic administration of an adeno-associated virus carrying codon-optimized WT-TMEM43 prevents ventricular dysfunction and ECG abnormalities induced by S358L-TMEM43.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Overexpression of WT-TMEM43 improves the pathological phenotype in a mouse model of ARVC5. Adeno-associated virus-mediated delivery of WT-TMEM43 offers a promising and specific therapy for patients suffering from this highly lethal disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT05885412, NCT06109181, and NCT06228924.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40091736/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40091736</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325848>10.1161/CIRCRESAHA.124.325848</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40091736</guid>
<pubDate>Mon, 17 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Laura Lalaguna</dc:creator>
<dc:creator>María Arévalo-Núñez de Arenas</dc:creator>
<dc:creator>Marina López-Olañeta</dc:creator>
<dc:creator>María Villalba-Orero</dc:creator>
<dc:creator>Rafael J Jiménez-Riobóo</dc:creator>
<dc:creator>María Victoria Gómez-Gaviro</dc:creator>
<dc:creator>Joan Isern</dc:creator>
<dc:creator>Pura Muñoz-Cánoves</dc:creator>
<dc:creator>Barry J Byrne</dc:creator>
<dc:creator>Juan Pablo Ochoa</dc:creator>
<dc:creator>Pablo García-Pavía</dc:creator>
<dc:creator>Enrique Lara-Pezzi</dc:creator>
<dc:date>2025-03-17</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Overexpression of Wild-Type TMEM43 Improves Cardiac Function in Arrhythmogenic Right Ventricular Cardiomyopathy Type 5</dc:title>
<dc:identifier>pmid:40091736</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325848</dc:identifier>
</item>
<item>
<title>High temperature and cardiovascular disease in Australia under different climatic, demographic, and adaptive scenarios</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40090366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Higher temperatures are expected to exacerbate the burden of CVD. This study highlights the need for urgent adaptation and mitigation efforts to minimize the negative health impacts of a warming climate on CVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 17:ehaf117. doi: 10.1093/eurheartj/ehaf117. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Cardiovascular disease (CVD), the leading cause of death globally and in Australia, is sensitive to heat exposure. This study assesses the burden of CVD attributable to high temperatures across Australia and projects future burden in the context of climate change.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Disability-adjusted life years for CVD, including years of life lost and years lived with disability, were sourced from the Australian Burden of Disease database. A meta-regression model was constructed using location-specific predictors and relative risks from prior literature to estimate relative risks of CVD mortality and morbidity due to high temperatures in the Australian context. The baseline CVD burden attributable to high temperatures in Australia for 2003-18 was calculated, and future burdens under two greenhouse gas emissions scenarios [Representative Concentration Pathways (RCP4.5 and RCP8.5)] for the 2030s and 2050s were projected, considering demographic changes and human adaptation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the baseline period, high temperatures accounted for 7.3% (95% confidence interval: 7.0%-7.6%) of the CVD burden in Australia, equivalent to 223.8 Disability-adjusted life years (95% confidence interval: 221.0-226.6) per 100 000 population. Future projections suggest a steady increase in the CVD burden across all scenarios examined. By the 2050s, under the RCP8.5 scenario that considers population growth and no adaptation, the total attributable burden of CVD is projected to more than double compared with the baseline, with the Northern Territory facing the most significant increase. These impacts could be mitigated with effective human adaptation to the warming climate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Higher temperatures are expected to exacerbate the burden of CVD. This study highlights the need for urgent adaptation and mitigation efforts to minimize the negative health impacts of a warming climate on CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40090366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40090366</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf117>10.1093/eurheartj/ehaf117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40090366</guid>
<pubDate>Sun, 16 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jingwen Liu</dc:creator>
<dc:creator>Blesson M Varghese</dc:creator>
<dc:creator>Alana Hansen</dc:creator>
<dc:creator>Keith Dear</dc:creator>
<dc:creator>Timothy Driscoll</dc:creator>
<dc:creator>Ying Zhang</dc:creator>
<dc:creator>Geoffrey Morgan</dc:creator>
<dc:creator>Vanessa Prescott</dc:creator>
<dc:creator>Vergil Dolar</dc:creator>
<dc:creator>Michelle Gourley</dc:creator>
<dc:creator>Anthony Capon</dc:creator>
<dc:creator>Peng Bi</dc:creator>
<dc:date>2025-03-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>High temperature and cardiovascular disease in Australia under different climatic, demographic, and adaptive scenarios</dc:title>
<dc:identifier>pmid:40090366</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf117</dc:identifier>
</item>
<item>
<title>Mitral valve leaflet diverticulum with infective endocarditis associated with eccentric regurgitation of the bicuspid aortic valve</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40088098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 15:jeaf092. doi: 10.1093/ehjci/jeaf092. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40088098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40088098</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf092>10.1093/ehjci/jeaf092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40088098</guid>
<pubDate>Sat, 15 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Xuejie Li</dc:creator>
<dc:creator>Lin Ma</dc:creator>
<dc:date>2025-03-15</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Mitral valve leaflet diverticulum with infective endocarditis associated with eccentric regurgitation of the bicuspid aortic valve</dc:title>
<dc:identifier>pmid:40088098</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf092</dc:identifier>
</item>
<item>
<title>Question: an uncommon electrocardiogram pattern in a case of acute chest pain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40086893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Acute Cardiovasc Care. 2025 Mar 15:zuaf019. doi: 10.1093/ehjacc/zuaf019. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40086893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40086893</a> | DOI:<a href=https://doi.org/10.1093/ehjacc/zuaf019>10.1093/ehjacc/zuaf019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40086893</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Gulbadin Mufti</dc:creator>
<dc:creator>Shahid H Shali</dc:creator>
<dc:creator>A Shaheer Ahmed</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>European heart journal. Acute cardiovascular care</dc:source>
<dc:title>Question: an uncommon electrocardiogram pattern in a case of acute chest pain</dc:title>
<dc:identifier>pmid:40086893</dc:identifier>
<dc:identifier>doi:10.1093/ehjacc/zuaf019</dc:identifier>
</item>
<item>
<title>Toward non-invasive assessment of myocardial work using myocardial stiffness and strain: a human pilot study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40085822/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Calculating segmental myocardial work based on myocardial stiffness and strain measurements is technically feasible. This approach overcomes the inherent limitations of current methods by introducing a direct quantitative measure of myocardial stress.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 14:jeaf089. doi: 10.1093/ehjci/jeaf089. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial work assessment has emerged as a promising tool for left ventricular (LV) performance evaluation. Existing non-invasive methods for assessing it rely on assumptions on LV pressure and geometry. Recently, shear wave elastography allowed to quantify changes in myocardial stiffness throughout the cardiac cycle. Based on Hooke's law, it becomes theoretically possible to calculate myocardial stress and work from myocardial stiffness and strain measurements. The main objective of this study is to demonstrate the feasibility of this comprehensive ultrasound approach and to compare myocardial work values between populations where variations are anticipated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Children with hypertrophic cardiomyopathy (HCM), aortic stenosis (AS) and healthy volunteers (HV) were included in this study. Segment dimensions, strain, thickness, and segmental myocardial stiffness were assessed in the basal anteroseptal segment throughout the cardiac cycle. One-beat segmental work, the stress-strain loop area, contributive and dissipative work were compared between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Twenty HV (9.8 ± 5.3 years of age), 20 HCM (10.0 ± 6.1 years of age) and 5 AS (5.3 ± 4.3 years of age) subjects were included. One-beat segmental work was significantly higher in AS (272.0 ± 102.9 µJ/mm) and lower in HCM (38.2 ± 106.9 µJ/mm) compared to HV (131.1 ± 83.3 µJ/mm), p=0.02 and p=0.01 respectively. Desynchronized work was prevailing in HCM with dissipative work during systole measured at 17.3 ± 28.9 µJ/mm and contributive work during diastole measured at 15.3 ± 18.0 µJ/mm. The stress-strain loop area was higher in AS (95.2 ± 31.1 kPa.%) and HV (66.2 ± 35.9 kPa.%) than in HCM (5.8 ± 13.0 kPa.%), p&lt;0.01.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Calculating segmental myocardial work based on myocardial stiffness and strain measurements is technically feasible. This approach overcomes the inherent limitations of current methods by introducing a direct quantitative measure of myocardial stress.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40085822/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40085822</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf089>10.1093/ehjci/jeaf089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40085822</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Maelys Venet</dc:creator>
<dc:creator>Jerome Baranger</dc:creator>
<dc:creator>Aimen Malik</dc:creator>
<dc:creator>Minh B Nguyen</dc:creator>
<dc:creator>Seema Mital</dc:creator>
<dc:creator>Mark K Friedberg</dc:creator>
<dc:creator>Mathieu Pernot</dc:creator>
<dc:creator>Clement Papadacci</dc:creator>
<dc:creator>Sebastien Salles</dc:creator>
<dc:creator>Rajiv Chaturvedi</dc:creator>
<dc:creator>Luc Mertens</dc:creator>
<dc:creator>Olivier Villemain</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Toward non-invasive assessment of myocardial work using myocardial stiffness and strain: a human pilot study</dc:title>
<dc:identifier>pmid:40085822</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf089</dc:identifier>
</item>
<item>
<title>Outcomes of Mechanical Circulatory Support Devices Among Patients with Mechanical Complications of Acute Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40085820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this large observational analysis of AMI hospitalizations, mechanical complications were rare and associated with very high in-hospital mortality. Although the use of MCS has increased, however, in-hospital mortality rates remain high even among patients who received MCS. Further investigations are needed to clarify the role of MCS devices among patients with mechanical complications of AMI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Acute Cardiovasc Care. 2025 Mar 14:zuaf039. doi: 10.1093/ehjacc/zuaf039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mechanical complications of acute myocardial infarction (AMI) are rare but associated with considerably high mortality. While guidelines suggest mechanical circulatory support (MCS) devices as a potential bridge to definitive therapy, studies supporting this recommendation are limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using data from the National Inpatient Sample, a large admirative database in the United States, years 2016-2020, we identified AMI admissions (ST-elevation and non-ST-elevation myocardial infarction) with mechanical complications (ventricular septal defect, free wall rupture, or papillary muscle rupture). Logistic regression models adjusting for potential confounders were used to assess temporal trends in MCS utilization and to compare in-hospital mortality between those who received MCS versus none.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,450,219 AMI patients, 7,025 (0.2%) had a mechanical complication of which, 3,115 patients (44.3%) received at least one MCS device. There was a rising trend in MCS use (39.3% in 2016 to 48.9% in 2020, Ptrend=0.02), but there was no corresponding reduction in the incidence of in-hospital mortality (36.9% in 2016 vs 43.4% in 2020, Ptrend=0.75). There was no significant difference in in-hospital mortality between those who received MCS versus those who did not (48.4 vs 34.5% respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this large observational analysis of AMI hospitalizations, mechanical complications were rare and associated with very high in-hospital mortality. Although the use of MCS has increased, however, in-hospital mortality rates remain high even among patients who received MCS. Further investigations are needed to clarify the role of MCS devices among patients with mechanical complications of AMI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40085820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40085820</a> | DOI:<a href=https://doi.org/10.1093/ehjacc/zuaf039>10.1093/ehjacc/zuaf039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40085820</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ahmed M Younes</dc:creator>
<dc:creator>Ahmed K Mahmoud</dc:creator>
<dc:creator>Ibrahim Kamel</dc:creator>
<dc:creator>Linus Williams</dc:creator>
<dc:creator>Ahmed Maraey</dc:creator>
<dc:creator>Mahmoud Khalil</dc:creator>
<dc:creator>Ahmed Elzanaty</dc:creator>
<dc:creator>Rodrigo Bagur</dc:creator>
<dc:creator>Abdulla A Damluji</dc:creator>
<dc:creator>Jacqueline E Tamis-Holland</dc:creator>
<dc:creator>Islam Y Elgendy</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>European heart journal. Acute cardiovascular care</dc:source>
<dc:title>Outcomes of Mechanical Circulatory Support Devices Among Patients with Mechanical Complications of Acute Myocardial Infarction</dc:title>
<dc:identifier>pmid:40085820</dc:identifier>
<dc:identifier>doi:10.1093/ehjacc/zuaf039</dc:identifier>
</item>
<item>
<title>Cardiac computed tomography for rule-out of ischemic heart disease in patients with new-onset heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40085773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: In stable patients with new-onset HF, cardiac CT may be considered as the primary imaging modality to rule out ischemic heart disease, and implementation of a CT-based strategy for ischemia rule-out may substantially reduce the need for invasive examination.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 14:jeaf090. doi: 10.1093/ehjci/jeaf090. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with new-onset heart failure (HF), invasive coronary angiography (ICA) is recommended to rule out coronary artery disease (CAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the utility of a coronary artery calcium score (CACS) and coronary computed tomography angiography (CCTA) for rule-out of obstructive CAD in patients with new-onset HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Patients with new-onset HF referred for cardiac computed tomography (CT) were included (2008-2022). Patients were grouped according to CACS and CCTA findings. Stenosis on CCTA was defined as ≥1 vessel with ≥50% luminal diameter stenosis. Obstructive CAD was defined as ≥1 vessel with ≥50% luminal diameter stenosis at ICA performed within 120 days from cardiac CT. Revascularization procedures within 120 days from cardiac CT were identified.Overall, 3336 patients were eligible. Obstructive CAD was ruled out in 2332/2780 patients (83.8%) with complete cardiac CT. 1032 (30.9%) patients had CACS=0 and 377 (11.3%) patients had CACS≥1000.18.0% of patients had stenosis on CCTA, ranging from 2.8% to 71.7% in patients with CACS=0 and CACS≥1000, respectively.Obstructive CAD at second-line ICA was diagnosed in 11.5% of patients, ranging from 1.2% to 47.2% in patients with CACS=0 and CACS≥1000, respectively. Revascularization was performed in 6.9% of patients, ranging from 0.6% to 26.5% in patients with CACS=0 and CACS≥1000, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: In stable patients with new-onset HF, cardiac CT may be considered as the primary imaging modality to rule out ischemic heart disease, and implementation of a CT-based strategy for ischemia rule-out may substantially reduce the need for invasive examination.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40085773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40085773</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf090>10.1093/ehjci/jeaf090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40085773</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Christina Boesgaard Graversen</dc:creator>
<dc:creator>Laust Dupont Rasmussen</dc:creator>
<dc:creator>Jens Sundbøll</dc:creator>
<dc:creator>Morten Würtz</dc:creator>
<dc:creator>Kristian Hay Kragholm</dc:creator>
<dc:creator>Morten Bøttcher</dc:creator>
<dc:creator>Simon Winther</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Cardiac computed tomography for rule-out of ischemic heart disease in patients with new-onset heart failure</dc:title>
<dc:identifier>pmid:40085773</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf090</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2024: the top 10 papers in thrombosis and antithrombotic treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40084811/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 14:ehaf126. doi: 10.1093/eurheartj/ehaf126. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40084811/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40084811</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf126>10.1093/eurheartj/ehaf126</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40084811</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Jurriën M Ten Berg</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2024: the top 10 papers in thrombosis and antithrombotic treatment</dc:title>
<dc:identifier>pmid:40084811</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf126</dc:identifier>
</item>
<item>
<title>Hepatopulmonary Syndrome or Portopulmonary Hypertension? Two Contrasting Cases of Exertional Hypoxemia From Liver Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40084409/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 14:e012506. doi: 10.1161/CIRCHEARTFAILURE.124.012506. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40084409/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40084409</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.012506>10.1161/CIRCHEARTFAILURE.124.012506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40084409</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Fadi Adel</dc:creator>
<dc:creator>Adel Kabbara Allababidi</dc:creator>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>Hepatopulmonary Syndrome or Portopulmonary Hypertension? Two Contrasting Cases of Exertional Hypoxemia From Liver Disease</dc:title>
<dc:identifier>pmid:40084409</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.012506</dc:identifier>
</item>
<item>
<title>Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40084403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250318041529&amp;v=2.18.0.post9+e462414
      <description>The most common form of hereditary transthyretin cardiac amyloidosis (hATTR-CA) in the United States and the United Kingdom is the p.V142I variant. About 3% to 4% of patients with African ancestry carry this genetic predisposition to develop signs and symptoms of hATTR-CA. Nevertheless, clinical manifestations of hATTR-CA appear only late in the fifth and sixth decades of life, despite its clear genetic background. Imbalances in native protein-stabilizing and elementary breakdown cellular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Heart Fail. 2025 Mar 14:e012469. doi: 10.1161/CIRCHEARTFAILURE.124.012469. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The most common form of hereditary transthyretin cardiac amyloidosis (hATTR-CA) in the United States and the United Kingdom is the p.V142I variant. About 3% to 4% of patients with African ancestry carry this genetic predisposition to develop signs and symptoms of hATTR-CA. Nevertheless, clinical manifestations of hATTR-CA appear only late in the fifth and sixth decades of life, despite its clear genetic background. Imbalances in native protein-stabilizing and elementary breakdown cellular mechanisms are postulated as potential causes for affecting transthyretin structural integrity and myocardial fibril deposition. Noncoding variants, epigenetic and environmental factors, as well as gut microbiome derangements may serve as disease-modifying factors that feature detrimental amyloidogenic organ involvement and impact disease severity. Organ amyloid deposition varies widely among different carriers of a genetic transthyretin variant. The genotype-phenotype interdependence causes unpredictable phenotypic penetrance that results in a variety of signs and symptoms and patient outcomes. Cardiovascular biomarkers and multimodality imaging may identify initial amyloidogenic organ involvement. These early clinical clues through the course of hATTR-CA offer a window of opportunity for early treatment onset to cease disease progression and alter prognosis. Identifying at-risk patients requires information on the genetic background of probands and their relatives. Initiatives to reveal asymptomatic gene carriers early in the disease should be encouraged, as it necessitates stringent patient follow-up and immediate treatment onset to reduce the burden of heart failure hospitalization and mortality in hATTR-CA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40084403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250318041529&v=2.18.0.post9+e462414">40084403</a> | DOI:<a href=https://doi.org/10.1161/CIRCHEARTFAILURE.124.012469>10.1161/CIRCHEARTFAILURE.124.012469</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40084403</guid>
<pubDate>Fri, 14 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Simon Vanhentenrijk</dc:creator>
<dc:creator>Justin L Grodin</dc:creator>
<dc:creator>Silvio Nunes Augusto</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:date>2025-03-14</dc:date>
<dc:source>Circulation. Heart failure</dc:source>
<dc:title>Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges</dc:title>
<dc:identifier>pmid:40084403</dc:identifier>
<dc:identifier>doi:10.1161/CIRCHEARTFAILURE.124.012469</dc:identifier>
</item>





























</channel>
</rss>